HENRY I. RUSSEK, M.D., F.A.C.P.; JOHN C. CUTLER, M.D.; STEPHEN A. FROMER, M.D.; BURTON L. ZOHMAN, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Most authorities agree that specific therapy in cardiovascular syphilis favorably influences the course of the disease and increases life expectancy.1 According to Scott2 "any medication that tends to allay the process in the aorta and thus prevent its spread to the aortic orifice or retard the development of aneurysm, may add years to the patient's life." Moore and his associates,3 using preparatory heavy metals to avoid the possibility of Herxheimer reaction, followed by conservative arsenotherapy, have reported striking effects on the mortality rate and the average duration of life in this form of the disease.
The demonstration by Mahoney, Arnold
RUSSEK HI, CUTLER JC, FROMER SA, et al. TREATMENT OF CARDIOVASCULAR SYPHILIS WITH PENICILLIN*. Ann Intern Med. 1946;25:957–959. doi: https://doi.org/10.7326/0003-4819-25-6-957
Download citation file:
Published: Ann Intern Med. 1946;25(6):957-959.
Infectious Disease, Sexually Transmitted Infections.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use